EU drug firms to China: open up, streamline, protect and talk
This article was originally published in SRA
Executive Summary
Lengthy delays in the approval of new drugs in China and inadequate protection of confidential data are among the main concerns in the latest policy position paper from the European Union Chamber of Commerce in the country1.